Enovis launches veterinary laser therapy system in U.S.

Enovis launches veterinary laser therapy system in U.S.

Gold slides as U.S.-Iran conflict lifts oil, hawkish Fed bets grow DALLAS - Enovis Corporation (NYSE:ENOV) announced today the U.S. launch of CT-RevitL, a veterinary laser therapy system from its Companion Animal Health business. The system uses photobiomodulation therapy to manage pain, accelerate tissue healing, reduce inflammation and support post-operative recovery in animals, according to a press release statement. The device incorporates COMPASS technology, a treatment guidance system designed to deliver calibrated dosing.

Laser therapy is used in veterinary medicine for musculoskeletal and soft-tissue conditions. Pet owners are seeking alternatives to drug-based treatments, the company stated. "CT-RevitL represents the next chapter in our commitment to deliver practical, innovative, evidence-based veterinary care," said Terry Ross, Group President of Enovis Prevention & Recovery business segment.

"We have been the trusted partner of veterinary teams across the U.S. for nearly two decades." Companion Animal Health has operated in the veterinary therapeutic laser technology market for more than 15 years. The business unit is part of Enovis, a medical technology company headquartered in Delaware.

CT-RevitL became available to veterinary practices across the United States starting today. The company plans international availability in subsequent phases. The launch includes a clinical education program and support from veterinary specialists.

Enovis develops medical technology solutions for patient outcomes and surgical applications. The company’s Companion Animal Health division focuses on veterinary medical technology and non-invasive treatments. With a market capitalization of $1.48 billion and revenue of $2.28 billion over the last twelve months, Enovis maintains a strong gross profit margin of 61%.

According to InvestingPro analysis, the stock appears undervalued at current levels, trading below its Fair Value. Investors can access detailed insights through the comprehensive Pro Research Report, available for ENOV and over 1,400 U.S. equities. The system is designed to integrate into veterinary practice workflows and support treatment protocols across various conditions.

The company stated the device aims to help practices expand treatment offerings and generate demand for non-drug care options. In other recent news, Enovis Corporation reported a strong first-quarter 2026 performance, with adjusted earnings per share of $0.89, surpassing the forecast of $0.81. The company’s revenue also exceeded expectations, reaching $589 million compared to the projected $573.02 million.

Additionally, Enovis shareholders approved an amendment to the 2020 Omnibus Incentive Plan, authorizing an additional 3,650,000 shares of common stock for issuance and increasing the compensation limits for outside directors. In another development, Enovis launched the DonJoy Spinamic Hybrid Scoliosis Brace in the U.S. market, which will be distributed by its subsidiary, DJO, LLC. The company also benefited from the Centers for Medicare & Medicaid Services’ decision to reverse reimbursement cuts for its non-invasive bone growth stimulators.

These recent developments reflect significant strides in Enovis’s operational and strategic initiatives.